CCM
LCTX icon

Cribstone Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Cribstone Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$103 Hold
88
– – ﹤0.01% 402
2022
Q3 		$0 Hold
88
– – ﹤0.01% 474
2022
Q2 		$0 Hold
88
– – ﹤0.01% 505
2022
Q1 		$0 Hold
88
– – ﹤0.01% 440
2021
Q4 		$0 Buy
+88
New +$206 ﹤0.01% 406

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cribstone Capital Management's LCTX Position: Q4 2022 in Review

Cribstone Capital Management held its Lineage Cell Therapeutics (LCTX) position steady in Q4 2022 at 88 shares worth $103. The position accounts for ﹤0.01% of the portfolio, ranked #402.

Cribstone Capital Management first reported a position in LCTX in Q4 2021 and has held it in 5 quarters since. 106 funds tracked by Wall St. Rank hold LCTX as of Q4 2022.

  • Cribstone Capital Management held 88 shares of Lineage Cell Therapeutics worth $103 as of Q4 2022.
  • Cribstone Capital Management left its Lineage Cell Therapeutics share count unchanged in Q4 2022.
  • Lineage Cell Therapeutics made up ﹤0.01% of Cribstone Capital Management's portfolio in Q4 2022, its #402 holding.
  • Cribstone Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • 106 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2022.

Based on Cribstone Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.